Jakafi 20 MG tablet 60S
Ended Awarded
- Contract number
- SPE2DB25FUJRA
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $12,090
Award facts
- Contract value 100% obligated
- $12,089.78 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order on August 1, 2025, by the Defense Logistics Agency (DLA) for JAKAFI 20 mg tablets (60-count units) with a ceiling value of $12,089.78. This firm fixed-price delivery order, which has an ultimate completion date of August 4, 2025, carries no set-aside designation. The award falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA valued at $499,999,999 through November 2026, which authorizes the agency to issue delivery orders for a comprehensive range of pharmaceutical products supporting the medical supply needs of Department of Defense healthcare facilities worldwide.
JAKAFI (ruxolitinib) is a prescription medication used in the treatment of myeloproliferative neoplasms and other hematologic conditions. This delivery order represents one of numerous pharmaceutical product deliveries DMS Pharmaceutical Group has secured from the DLA, including branded and generic prescription drugs, biologics, and medical consumables. The company's positioning as a critical supplier in the federal pharmaceutical supply chain reflects its ongoing role in supporting military healthcare operations across the United States and internationally.
Quick answers
Who was awarded contract SPE2DB25FUJRA?
SPE2DB25FUJRA was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on August 1, 2025.
How much is contract SPE2DB25FUJRA worth?
The government has obligated $12,090 on SPE2DB25FUJRA.
Is contract SPE2DB25FUJRA an order under another contract?
Yes. SPE2DB25FUJRA is a delivery order under SPE2DB25D9365, an indefinite delivery contract.
Was contract SPE2DB25FUJRA competed?
The extent of competition for SPE2DB25FUJRA was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award